| |
| Vol. 3, No. 7 |
July 2004 |
|
Jerry Bylander, Editor jerryby@cableone.net |
| The Director's Column |
|
| Next Meeting |
|
Speaker: : Sam Bevilacqua, Augusta Medical Systems
Topic: Erectile Dysfunction Aids:
There are a number of treatments for ED including Viagra, injections,
vacuum devices and a surgical implant. These options will be briefly
described with the emphasis on the vacuum device. This option is the one
used before the implant option when all other techniques have failed. Sam
will also express the company’s opinions concerning the importance of
regular exercise with their device, following radiation or a
prostatectomy. |
| Last Meeting |
| Date & Time: | Tuesday, January 20, 2004, 7:00 PM |
| Place: | Wilson N. Jones, North Campus |
| Attendance: | approximately 6 attendees |
|
None New Business We discussed ideas for increasing attendence. Program: "What
are your questions and Concerns About Prostate Cancer" Speaker: Michael
Hilz, M.D.
300 N. Highland, Ste. 365, Sherman and a Lupron
representative to answer questions about hormonal therapy as well as R.B.
McGowen USToo! Texoma founder and long time survivor on hormonal therapy. The meeting adjourned about 9 PM. Henri Plunkett, Program Chair/by the Editor |
| Other Important Events |
| Your organization's meetings listed here. Contact the Editor at jerryby@cableone.net |
| Editor's Notes |
June 8, 2004
"Two Drugs Found to Help in Prostate and Brain Cancers"
By ANDREW POLLACK
NEW ORLEANS, June 7 - "The drug Taxotere can extend the lives of prostate cancer patients after hormonal therapy fails, giving men a new last-ditch option for treatment, according to the results of two clinical trials presented here Monday.
Another study showed for the first time that adding chemotherapy to radiation treatment prolongs survival for people with a type of brain cancer that usually kills within months."
.However, Pollack points out that those of for whom initial therapy fails and are on hormone deprivation therapy, that eventually that treatment will fail. Until now there have been few alternative treatments following the failure of hormone therapy. However with the promise of Taxotere, chemotherapy will become an alternative treatment.
"But in the two clinical trials, which differed somewhat in design, those who got Taxotere, also known as docetaxel, lived a median of 18 to 19 months, compared with about 16 months for those who got the drug now typically given to relieve pain as the cancer spreads."
The side effects of Taxotere can be nausea, vomiting and blood clots, and a risk of infection. These are offset by the 2 to 3 month average increase in life expectancy, and promise a further improvement if given earlier.